|Bid||25.920 x 68800|
|Ask||26.500 x 1500|
|Day's Range||26.245 - 26.970|
|52 Week Range||16.480 - 26.970|
|PE Ratio (TTM)||32.05|
|Dividend & Yield||0.54 (1.85%)|
|1y Target Est||N/A|
Celgene and Grifols are former leaders, but enough time has passed to give them a new shine.
Is Grifols a great pick from the value investor's perspective right now? Read on to know more.
Young blood loaded with a particular protein, which is less plentiful as people age, could rejuvenate learning and memory, Stanford University researchers said in a paper released today. It would take even longer to make drugs that mimic the protein. Ultimately, San Carlos' Alkahest Inc., which has rights to license the research, and Barcelona-based Grifols S.A. (GRFS) could market treatments aimed at age-associated declines in learning skills and memory, but not necessarily targeting memory-robbing Alzheimer's disease.